Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elecoglipron vs oral semaglutide in type 2 diabetes mellitus with increased cardiovascular risk (Eluminate-2)
jRCT2031260258Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
01
Overview
Randomised trial in type 2 diabetes mellitus (T2DM) and cardiac morbidity comparing Elecoglipron once-daily with Oral semaglutide once-daily (2 arms). Primary endpoint: Change from baseline in Hemoglobin A1c (HbA1c). Started Jul 2026; status: recruiting.
02
Drugs
elecoglipronsemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on jRCT2031260258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260258.